ASX Filings

Becoming a substantial holder

August 3, 2023

ASRS 2023 - PK and safety of sozinibercept (OPT-302)

August 1, 2023

OPT Announces Sozinibercept as the Drug Name for OPT 302

July 27, 2023

Opthea Presents at the 2023 Ophthalmology Innovation Summit

July 25, 2023

Opthea to Feature at the ASRS 2023 Annual Meeting

July 14, 2023

Opthea Announces Appointment of Snr Medical Advisor

July 11, 2023

Change in substantial holding

June 23, 2023

Opthea Appoints Anshul Thakral as Non-Executive Director

June 9, 2023

Initial Director's Interest Notice AT

June 9, 2023

Final Director's Interest Notice MS

June 8, 2023